CClinicalTrials.gg
Sign In
Status unknownNCT02933190Updated Oct 14, 2016

Fertility After Transvaginal Surgery or Uterine Artery Embolization Combined With Uterine Curettage in Patients With Cesarean Scar Pregnancy

An interventional study of transvaginal surgery；UAE and D&C in Magnetic Resonance Imaging, Ovarian Function and Menstruation, sponsored by Shanghai First Maternity and Infant Hospital. Status unknown at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Shanghai First Maternity and Infant Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Sex
Female
01

Study summary

To investigate the fertility in patients after treatment by transvaginal surgery or uterine artery embolization combined with uterine curettage

02

Conditions studied

  • Magnetic Resonance Imaging
  • Ovarian Function
  • Menstruation
03

In context

Lead sponsor

Shanghai First Maternity and Infant Hospital is the lead sponsor of 45 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • increased levels of serum β-hCG and ultrasonography findings. The criteria for diagnosis by ultrasonography was the presence of the following: (1) an empty uterine cavity and endocervical canal; (2) detection of the placenta and/or a gestational sac embedded in the hysterectomy scar; (3) the presence of the gestation sac with or without a fetal pole and with or without fetal cardiac activity (depending on the gestational age) in the anterior part of the uterine isthmus; and (4) a thin (1-3 mm) or absent myometrial layer between the gestational sac and the bladder(24). All patients had taken Magnetic Resonance Imaging (MRI) to clarify the diagnosis . Pregnancy tissues were identified by histopathology examinations of the surgical tissues.

Exclusion criteria

Exclusion Criteria:

  • All enrolled patients had no contraindications for transvaginal surgery or UAE, including renal failure, active pelvic infection, clotting disorders, or known allergy to the contrast material.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Other
    CSP；transvaginal surgery；UAE and D&C

    Cesarean scar pregnancy (CSP) refers to the implantation of a gestational sac with the myometrium at the site of a previous cesarean scar

    Procedure: transvaginal surgery；UAE and D&C

Interventions

  • Proceduretransvaginal surgery；UAE and D&C

    For cesarean scar pregnancy treatment

06

What researchers measure

Primary outcomes

  1. Duration of menstruation by questionnaire (days)

    Time frame: six months after treatment

  2. Endocrine level by blood examination (FSH in IU/L)

    Time frame: six months after treatment

  3. Volume of menstruation by questionnaire (in pictorial blood loss score)

    Time frame: six months after treatment

Secondary outcomes

  1. The length of the CSD by MRI (millimeter)

    Time frame: six months after treatment

  2. The width of the CSD by MRI (millimeter)

    Time frame: six months after treatment

  3. The depth of the CSD by MRI (millimeter)

    Time frame: six months after treatment

07

Study locations

1 site
  • Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University
    Shanghai, Shanghai 201204, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02933190
Lead sponsor
Shanghai First Maternity and Infant Hospital
Responsible party
Sponsor
First posted
Oct 14, 2016
Start date
Nov 2016
Primary completion
Aug 2018 (estimated)
Completion
Dec 2019 (estimated)
Last update
Oct 14, 2016

Study contacts

Xipeng Wang
Contact
xipengwang@hotmail.com
0086-13817806602
Huihui Chen
Contact
huihui78505@hotmail.com
0086-13916278505
Xipeng Wang
study chair · Department of Gynecology, Shanghai First Maternity and Infant Hospital, affiliated to Tongji University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Shanghai First Maternity and Infant Hospital

Start the discussion